Phase 4 N=30 Treatment

Continuous Double Ovarian Stimulation.

Fertility Issues

Bottom Line

View on ClinicalTrials.gov: NCT05815719 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2025

Primary outcome: Primary: Total Number of Retrieved Oocytes — 13.33; 11.87 oocytes

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Corifollitropin Alfa (Drug); Follitropin Alfa (Drug); Follitropin Alfa Biosimilar (Drug); Urinary Human follicle stimulating hormone (Drug)
Age: Adult · 18+ yrs
Sex: Female
Sponsor: Instituto Bernabeu
Primary completion: Apr 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Total Number of Retrieved Oocytes	13.33; 11.87	—
PRIMARY Number of MII Oocytes	10.4; 9.2	—
SECONDARY Duration of Ovarian Stimulation	24.4; 25.2	—
SECONDARY Number of Injections	4.5; 35.2	—

Summary

To evaluate the efficacy of the weekly use of corifollitropin alfa in double ovarian stimulation process and to compare it to the conventional protocol with daily medication administration.

Eligibility Criteria

Inclusion Criteria

Patients with indication for DUOSTIM protocol
Maximum age of 43 years (up to one day before their 44th birthday) at the beginning of the stimulation process.
Ability to participate and comply with the study protocol.
To have given written consent

Exclusion Criteria

Finding of ovarian pathology at the time of initiation of stimulation: e.g. ovarian cysts.
Concurrent participation in another study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05815719). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.